Epitomics

Aushon Biosystems has launched Cira, its new multiplex immunoassay platform.

Bio-Rad this week introduced its V3 Western Workflow, a portfolio of products for Western blotting that include its TGX Stain-Free gels, ChemiDox MP imaging system, and TransBlot Turbo transfer system.

Epitomics has released new rabbit monoclonal antibodies for a variety of proteins including phospho LRRK2, TTF1, CHx10, and LSD1.

NanoInk this week released its new NanoArray Assay System for the automated analysis of its protein NanoArray assays.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma for mass spec workflows like SISCAPA and immuno-MALDI.

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.